North American Pediatric Allergy and Asthma Congress 2024

Las Vegas, NV US
April 12, 2024 to April 14, 2024

Early Bird Pricing: $395 for ACAAI/CSACI members, $595 non-members, $125 students/residents/FITs, $695 non-exhibiting industry attendees

After February 2, 2024, $595 for ACAAI/CSACI members, $795 non-members, $225 students/residents/FITs, $795 non-exhibiting industry attendees

**CSACI members only - use coupon code CSACI24 during checkout for discounted price**

imageDon’t miss this exciting opportunity to be part of the 2nd North American Pediatric Allergy and Asthma Congress (NAPAAC) that will take place April 12-14, 2024, at the JW Marriott Las Vegas Resort & Spa. This 3-day CME program – developed jointly by the American College of Allergy, Asthma and Immunology (ACAAI) and the Canadian Society of Allergy and Clinical Immunology (CSACI) – will focus entirely on pediatric allergies and related conditions.

NAPAAC aims to deliver state of the art evidence-based practical approaches to assist diagnosis and management of common pediatric conditions. Sessions are designed to be engaging, interactive, and entertaining. Attendees will not only learn pearls to apply immediately into clinical practice, but will hear experts in the specialty of allergy/immunology offer insight and perspective regarding new paradigms of care.

Plan now to join us for NAPAAC 2024: Advances in Pediatric Allergy: Moving Towards Proactive Management

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 15.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 15.75 contact hours. 

Target Audience

Allergists, pediatricians and other allergy healthcare providers.

Learning Objectives

At the conclusion of this activity learners should be able to…

1.    Translate new evidence regarding treatment of allergic conditions into clinical practice
2.    Incorporate shared decision making with patients surrounding various management options
3.    Utilize an individualized approach for patients with food allergy, allergic rhinitis and asthma
4.    Increase awareness surrounding paradigm shifts in prevention, diagnosis and management

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 15.75 AMA PRA Category 1 Credit™
  • 15.75 Attendance
  • 15.75 CBRN
Course opens: 
11/01/2023
Course expires: 
12/31/2024
Event starts: 
04/12/2024 - 1:00pm CDT
Event ends: 
04/14/2024 - 2:30pm CDT
Cost:
$695.00
Add to calendar: 
Rating: 
0

Download as a PDF

                                     NAPAAC 2024 PROGRAM
FRIDAY APRIL 12  
11:00 am - 1:00 pmRegistration 
1:00 pm - 1:15 pmWelcome/IntroductionsDavid Stukus, MD, Douglas Mack, MD, MSc
1:15 pm - 2:00 pmKeynote Presentation
Overcoming Inertia: Implementing Current Evidence Based Medicine into Clinical Practice		Timothy Caulfield, BSc, LL.B, LL.M
2:00 pm - 2:30 pmLet the Babies Eat: Instilling Confidence Surrounding Early Introduction of Allergenic FoodsMimi Tang, MBBS, PhD
2:30 pm - 3:00 pm Prognosis from an Early Age: How to use Phenotyping to Guide Management of Asthma, Atopic Dermatitis, and Food AllergyDavid Stukus, MD
3:00 pm - 3:15 pmQ & ADouglas Mack, MD, MSc, David Stukus, MD
3:15 pm - 3:30 pmBreak  
3:30 pm - 4:00 pmPro/Con: Penicillin Allergy Delabeling Should be Done in Primary Care OfficesMaureen Petersen, MD, Moshe Ben-Shoshan, MD, MSc
4:00 pm - 4:30 pmLessons Learned From the COVID-19 Pandemic: Why We Can’t Go Back to the Way Things WereVictoria Cook, MSc, MD
4:30 pm - 5:30 pmHappy Hour/Fireside Chat with Dave and FriendsDavid Stukus, MD, Timothy Caulfield, BSc, LL.B, LL.M, Mimi Tang, MBBS, PhD
5:45 pm - 7:15 pmNonCME Industry Forum Dinner 
SATURDAY APRIL 13  
7:00 am - 7:45 amBreakfast Symposium
New Paradigms in the Management of Anaphylaxis		Jay Lieberman, MD
7:45 am - 8:30 am Keynote Presentation
If You're Not Using Shared Decision Making for Atopic Conditions, then You're Doing it All Wrong		Matthew Greenhawt, MD, MBA, MSc
8:30 am- 9:00 amManaging Asthma in Children: When to Step Up and When to Step DownWilliam Anderson, MD
9:00 am - 9:15 am Q & ADouglas Mack, MD, MSc, David Stukus, MD
9:15 am - 9:45 amBreak/Visit Exhibit Hall 
9:45 am - 10:15 amWhy Everything You Thought You Knew About Atopic Dermatitis is OutdatedVikash Oza, MD
10:15 am - 10:45 amThe Most Practical Talk About Diagnosing Food Allergy That You’ve Ever Heard (AKA: Why panel food testing really hurts)Mariam Hanna, MD
10:45 am - 11:15 am  Who, When, Why and How to Start an Evaluation for Primary Immune DeficiencyBen Prince, MD, MSCI
11:15 am - 11:45 am Pro/Con: Baked Food Ingestion Hastens the Resolution of Food AllergyAnna Nowak-Wegrzyn, MD, PhD
Mimi Tang, MBBS, PhD
11:45 am - 12:00 pm Fido’s Gotta Go: Top 10 Practical Tips for Managing Allergic Rhinoconjunctivitis in ChildrenSyed Shahzad Mustafa, MD 
12:00 pm - 12:10 pm Q & ADavid Stukus, MD, Douglas Mack, MD, MSc
12:10 pm - 1:00 pm Lunch in Exhibit Hall 
1:00 pm - 1:45 pmSelecting the Best Biologic for Your PatientShahzad Mustafa, MD 
1:45 pm - 2:45 pmBreakout Session 1A
Challenging Cases: Diagnostic Dilemmas (Immune deficiency, non-IgE food allergy, asthma, adverse drug reactions)		William Anderson, MD, Ben Prince, MD, MSCI, Anna Nowak-Wegrzyn, MD, PhD, Moshe Ben-Shoshan, MD, MSc
1:45 pm - 2:45 pmBreakout Session 2A
Challenging Cases: Management Dilemmas (Asthma, atopic dermatitis, adverse vaccine/drug reactions)		Vikash Oza, MD, Shahzad Mustafa, MD, Matthew Greenhawt, MD, MBA, MSc, Maureen Peterson, MD
1:45 pm - 2:45 pmBreakout Session 3A
Challenging Cases: Dr. Google, Nonadherence, and Resistance to Change		Purvi Parikh, MD, Mariam Hanna, MD, David Stukus, MD
2:45 pm - 3:15 pmBreak in Exhbit Hall / Change Breakouts 
3:15 pm - 4:15 pm Breakout Session 1B
Challenging Cases: Diagnostic Dilemmas (Immune deficiency, non-IgE food allergy, asthma, adverse drug reactions)		William Anderson, MD, Ben Prince, MD, MSCI, Anna Nowak-Wegrzyn, MD, PhD, Moshe Ben-Shoshan, MD, MSc
3:15 pm - 4:15 pm Breakout Session 2B
Challenging Cases: Management Dilemmas (Asthma, atopic dermatitis, adverse vaccine/drug reactions)		Vikash Oza, MD, Shahzad Mustafa, MD, Matthew Greenhawt, MD, MBA, MSc, Maureen Peterson, MD
3:15 pm - 4:15 pm Breakout Session 3B
Challenging Cases: Dr. Google, Nonadherence, and Resistance to Change		Purvi Parikh, MD, Mariam Hanna, MD, David Stukus, MD
4:20 pm - 5:00 pmStump the Expert with Doug and FriendsDouglas Mack, MD, MSc
5:00 pm - 6:00 pmNAPAAC Reception Social Hour in the Exhibit Hall 
6:15 pm - 7:45 pmNonCME Industry Forum Dinner 
SUNDAY APRIL 14  
7:00 am - 8:00 amBreakfast Symposium
How to Use Shared Decision Making to Guide Management of Eosinophilic Esophagitis		Natacha Tardio, MD
8:00 am - 8:30 amChanging the course of allergic rhinitis – a focus on sublingual immunotherapyDouglas Mack, MD, MSc
8:30 am - 9:00 amPro/Con: Mast Cell Activation Syndrome is More Common Than We ThinkMoshe Ben-Shoshan, MD, MSc, Matthew Greenhawt, MD, MBA, MSc
9:15 am  - 9:30 amQ&ADavid Stukus, MD, Douglas Mack, MD, MSc
9:30 am - 10:00 amBreak/Visit Exhibit Hall 
10:00 am - 10:30 amIt’s Time to Rethink Our Use of First Generation AntihistaminesElissa Abrams, MD, MPH
10:30 am - 11:00 amFood Oral Immunotherapy: Risks, Benefits, and Expected OutcomesMimi Tang, MBBS, PhD
11:00 am - 11:30 amTransitioning Adolescents with Allergic Conditions Towards IndependenceWilliam Anderson, MD
11:30 pm - 12:00 pmThe Best Mandatory Wellness Talk You’ll Ever GetDavid Stukus, MD
12:00 pm - 12:15 pmQ & ADouglas Mack, MD, MSc
12:15 pm - 12:30 pmClosing RemarksDavid Stukus, MD, Douglas Mack, MD, MSc

Download as a PDF

 

JW Marriott Las Vegas Resort & Spa
221 North Rampart Blvd.
Las Vegas, NV 89145
United States
+1 (877) 622-3140

Hotel Room Rate & Resort Fee:  $219 Single / Double + 13% tax and a reduced Resort Fee of $40 / night

Reserve Online:  https://book.passkey.com/e/50547027

Planners, Faculty & Disclosures

All identified relevant financials relationships with ineligible companies have been mitigated.

Elissa Abrams, MD: Planner, Speaker - no relevant financial relationships with ineligible companies to disclose
William  Anderson, MD: Speaker - Advisor: Genentech, Regeneron, Sanofi
Moshe Ben-Shosham, MD, MSc: Planner, Speaker - Speaker: Novartis, Stallergenes Greer, Sanofi, Medexsus
Timothy Caulfield, BSc, LL.B, LL.M: Speaker - no relevant financial relationships with ineligible companies to disclose
Victoria Cook, MSc, MD: Planner, Speaker - Speaker: Aralez Pharma, Pfizer
Matt Greenhawt, MD, MBA, MSc: Speaker - Advisor: AstraZeneca, Alk-Abello, DBV Technologies, Genentech, Novartis; Researcher: DBV Technologies, Novartis
Mariam Hanna, MD: Planner, Speaker - Advisor: ALK, Trudell; Speaker: ALK, Covis, Trudell, Medexus, Pfizer, Researcher: ALKDBV, AstraZeneca; Consultant: ALK
Jay Lieberman, MD: Speaker - Researcher: DBV Technologies, Novartis, Regeneron
Douglas Mack, MD: Co-Chair, Planner, Speaker - Researcher: DBV, AstraZeneca, Dermavent, Arcutis, ALK; Speaker: Bausch, Covis, Medexus
Syed Shahzad Mustafa, MD: Speaker - Speaker: Genentech, AstraZeneca, GlaxoSmithKline, Regeneron; Advisor: AstraZeneca
Anna Nowak-Wegrzyn, MD: Planner, Speaker - Advisor: Nestle; Speaker: Nutricia, Thermofisher Scientific; Researcher: Nutricia, DBV; Consultant: Nestle, Labcorp, Hamimmune
Vikash Oza, MD: Speaker - Consultant: Dermavant, Regeneron, Apogee; Advisor: Cerave; Researcher: Pfizer
Purvi Parikh, MD: Planner, Speaker - Advisor: Genentech, Moderna, Takeda; Speaker: AstraZeneca, Takeda
Maureen Petersen, MD: Planner, Speaker - no relevant financial relationships with ineligible companies to disclose
Benjamin T. Prince, MD, MSCI: Planner, Speaker - Advisor, Sanofi
David Stukus, MD, FACAAI: Co-Chair, Planner, Speaker - Researcher: DBV Technologies; Consultant: Kaleo Pharmaceuticals, Novartis, ARS Pharmaceuticals
Mimi Tang, MBBS, PhD: Speaker - Advisor: Novartis
Natacha Tardio, MD: Speaker - Advisor: Sanofi; Speaker: Sanofi, Amgen, AstraZeneca

Staff Disclosures
Jasmin Lidington, CAE: Planner - no relevant financial relationships with ineligible companies to disclose
Mary Carol Badat, MAdEd: Planner - no relevant financial relationships with ineligible companies to disclose

 

Available Credit

  • 15.75 AMA PRA Category 1 Credit™
  • 15.75 Attendance
  • 15.75 CBRN

EXHIBITORS & INDUSTRY PARTNERS

Don’t miss this exciting opportunity to be part of the 2nd North American Pediatric Allergy and Asthma Congress (NAPAAC) that will take place April 12-14, 2024, at the JW Marriott Las Vegas Resort & Spa. This 3-day CME program – developed jointly by the American College of Allergy, Asthma and Immunology (ACAAI) and the Canadian Society of Allergy and Clinical Immunology (CSACI) – will focus entirely on pediatric allergies and related conditions, with cuttting-edge, interactive presentations.

Plan now to exhibit at NAPAAC 2024: Advances in Pediatric Allergy: Moving Towards Proactive Management. A wide variety of sponsorship opportunties are also available. 

Download the EXHIBITOR & SPONSORSHIP PROSPECTUS

Price

Cost:
$695.00
Please login or create an account to take this course.

**CSACI members - use coupon code CSACI24 during checkout for discounted price**

Questions about making a payment? We use PayPal to process credit card payments, but you do not need a PayPal account to register.
Download our instructional sheet